Profil
Ruth Devenyns currently works at FlandersBio vzw, as Director and Biocartis SA, as Non-Executive Director.
Ms. Devenyns also formerly worked at Applied Maths NV, as Chairman, PR Pharmaceuticals, Inc., as Director, MDxHealth SA, as Independent Non-Executive Director, Ceres, Inc. (California), as Director from 2010 to 2011, deVGen NV, as Independent Non-Executive Director in 2012, Ablynx NV, as Director, Altea Therapeutics Corp., as Director, KBC Private Equity NV, as Investment Director from 2001 to 2012, MyCartis NV, as Director, PharmaNeuroBoost NV, as Director, Biocartis Group NV, as Non-Executive Director, KBC Securities NV, as Analyst in 2001, Korys Management NV, as Senior Advisor from 2013 to 2016, and Ogeda SA, as Chief Financial Officer.
Ms. Devenyns received her graduate degree in 1986 from Ghent University.
Postes actifs de Ruth Devenyns
| Sociétés | Poste | Début |
|---|---|---|
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Directeur/Membre du Conseil | 25/05/2011 |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit networking organization for the life sciences and biotechnology | Directeur/Membre du Conseil | 24/05/2011 |
Anciens postes connus de Ruth Devenyns
| Sociétés | Poste | Fin |
|---|---|---|
Korys Management NV
Korys Management NV Investment ManagersFinance Korys invests in companies located in Belgium. The firm focuses on conscious consumer, energy transition and healthy living sectors. It participates in buyout and early stage transactions with an investment size of EUR 5 - 15 million. The firm also makes investment in private equity funds. | Director of Investments | 28/02/2016 |
PharmaNeuroBoost NV
PharmaNeuroBoost NV Miscellaneous Commercial ServicesCommercial Services Develops pharmaceutical products | Directeur/Membre du Conseil | 05/12/2013 |
deVGen NV
deVGen NV BiotechnologyHealth Technology Provides biotechnology services for the pharmaceutical and agrochemical industries | Directeur/Membre du Conseil | 01/12/2012 |
KBC Private Equity NV
KBC Private Equity NV Investment ManagersFinance KBC Private Equity is an active, long-term manager which typically invests between €2 million and €50 million in medium-sized unlisted companies primarily in Belgium, Central and Eastern Europe. The firm targets performing businesses in diverse sectors which usually demonstrate a positive EBITDA of at least €1.5 million, focusing on companies which have built up a leading position in a specific sector and which have identified growth opportunities. Specific criteria apply for investments in the biotech industry. The firm takes both majority and minority interests in companies, partnering with the other shareholders and investee company management. In addition to providing equity and/or mezzanine financing, they aim to create value in areas where they are skilled, without participating in the day-to-day operational policy of the investee company. KBC Private Equity generally seeks a seat on the Board of Directors. The firm aims to contribute to investee companies by evaluating their internal and external growth opportunities, optimizing their financial structure, introducing new customer and supplier relationships, improving reporting systems and sharing specific industry knowledge. Their typical holding period is five to seven years for most of their investment projects. | Director of Investments | 01/03/2012 |
KBC Securities NV
KBC Securities NV Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 12/11/2001 |
Formation de Ruth Devenyns
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
PR Pharmaceuticals, Inc.
PR Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes bioactive compounds | Health Technology |
MDxHealth SA
MDxHealth SA Medical SpecialtiesHealth Technology Develops and commercializes epigenetic tests & services for cancer assessment | Health Technology |
KBC Securities NV
KBC Securities NV Investment Banks/BrokersFinance Provides brokerage services | Finance |
Korys Management NV
Korys Management NV Investment ManagersFinance Korys invests in companies located in Belgium. The firm focuses on conscious consumer, energy transition and healthy living sectors. It participates in buyout and early stage transactions with an investment size of EUR 5 - 15 million. The firm also makes investment in private equity funds. | Finance |
Ceres, Inc. (California)
Ceres, Inc. (California) Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit driving sustainability via investor and corporate networks for climate action, water stewardship and nature restoration | Commercial Services |
deVGen NV
deVGen NV BiotechnologyHealth Technology Provides biotechnology services for the pharmaceutical and agrochemical industries | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Develops and produces antibodies | Health Technology |
Altea Therapeutics Corp.
Altea Therapeutics Corp. Medical DistributorsDistribution Services Develops pharmaceutical products | Distribution Services |
Ghent University
Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Health Technology |
KBC Private Equity NV
KBC Private Equity NV Investment ManagersFinance KBC Private Equity is an active, long-term manager which typically invests between €2 million and €50 million in medium-sized unlisted companies primarily in Belgium, Central and Eastern Europe. The firm targets performing businesses in diverse sectors which usually demonstrate a positive EBITDA of at least €1.5 million, focusing on companies which have built up a leading position in a specific sector and which have identified growth opportunities. Specific criteria apply for investments in the biotech industry. The firm takes both majority and minority interests in companies, partnering with the other shareholders and investee company management. In addition to providing equity and/or mezzanine financing, they aim to create value in areas where they are skilled, without participating in the day-to-day operational policy of the investee company. KBC Private Equity generally seeks a seat on the Board of Directors. The firm aims to contribute to investee companies by evaluating their internal and external growth opportunities, optimizing their financial structure, introducing new customer and supplier relationships, improving reporting systems and sharing specific industry knowledge. Their typical holding period is five to seven years for most of their investment projects. | Finance |
MyCartis NV
MyCartis NV BiotechnologyHealth Technology Develops technologies for healthcare personalization needs | Health Technology |
Applied Maths NV
Applied Maths NV Packaged SoftwareTechnology Services Develops biosciences software | Technology Services |
PharmaNeuroBoost NV
PharmaNeuroBoost NV Miscellaneous Commercial ServicesCommercial Services Develops pharmaceutical products | Commercial Services |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit networking organization for the life sciences and biotechnology | Commercial Services |
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Health Technology |
Biocartis Group NV
Biocartis Group NV Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Health Technology |
Precirix NV
Precirix NV Pharmaceuticals: MajorHealth Technology Develops radiopharmaceuticals for cancer treatment | Health Technology |
















